Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

MDMA board: The Medical Device Manufacturers Association announced July 23 the addition of three new board members: George Neal, Abbott Medical Optics divisional VP for global refractive and cataract sales; Lynn Salo, VP for breast aesthetics sales and marketing at Allergan; and Eric Meier, president and CEO of Calypso Medical

You may also be interested in...



People In Brief

Von Eschenbach: Former FDA commissioner Andrew von Eschenbach will split his time between MD Anderson and the regulatory consulting firm Greenleaf Health LLC, which he will join as senior advisor. He returns to the University of Texas MD Anderson Cancer Center in Houston as an adjunct professor and will also serve on the advisory board of the David Koch Center for Applied Research in Genitourinary Cancers. On the policy side, von Eschenbach says he will use Greenleaf Health as a "launching pad" to participate in the discussion of macro health issues like personalized medicine, genomics and informatics. Von Eschenbach resigned as FDA commissioner upon the inauguration of President Obama; his successor has not yet been named

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

 

 

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

Topics

UsernamePublicRestriction

Register

MT027747

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel